Literature DB >> 14615621

Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function.

Sophie Gautier1, Olivier Petrault, Patrick Gele, Maud Laprais, Michelle Bastide, Anne Bauters, Dominique Deplanque, Brigitte Jude, Jacques Caron, Régis Bordet.   

Abstract

BACKGROUND AND
PURPOSE: In a model of mechanical focal ischemia, we investigated the involvement of thrombolysis products (TLP) in recombinant tissue plasminogen activator (rtPA)-induced intracerebral complications and the effects on infarct volume and postischemic endothelial function.
METHODS: Hemorrhage incidence and severity were evaluated by histomorphometric analysis in male spontaneously hypertensive rats (SHR) subjected to 60-minute intraluminal middle cerebral artery (MCA) occlusion and receiving intravenously 5 hours later either saline, rtPA (3, 10, or 30 mg/kg), or rtPA (10 mg/kg) associated with TLP (rtPA+TLP). In addition, MCA reactivity was assessed in rtPA- or rtPA+TLP-treated SHR versus control Wistar-Kyoto rats or SHR.
RESULTS: No hemorrhage was observed visually in SHR receiving saline. In contrast, rtPA administration induced hemorrhagic complications in infarcted areas in a dose-independent manner. Administration of rtPA+TLP solution, containing a high concentration of plasmin, did not affect hemorrhage incidence but significantly increased hemorrhage severity (8.8+/-2.3 petechiae versus 3.0+/-1.0 petechiae in rtPA group; P<0.001). This increased severity was associated with a significant increase of both infarct volume (182+/-10 versus 144+/-15 mm3 in rtPA group; P<0.01) and postischemic impairment of MCA endothelium-dependent relaxation (9+/-0.5% versus 13+/-1% in rtPA group; P<0.05).
CONCLUSIONS: Treatment with rtPA led to intracerebral hemorrhages, in contrast to saline-treated animals, and the presence of TLP increased the severity of these hemorrhages, in parallel with increased infarct volume and worsened endothelial function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14615621     DOI: 10.1161/01.STR.0000101914.62066.7B

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  17 in total

Review 1.  The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicity.

Authors:  George W J Harston; Brad A Sutherland; James Kennedy; Alastair M Buchan
Journal:  J Cereb Blood Flow Metab       Date:  2010-08-25       Impact factor: 6.200

2.  Outcome in acute stroke with different intra-arterial infusion rate of urokinase on thrombolysis.

Authors:  X Gan; Y Luo; F Ling; X Ji; J Chen; Y Ding
Journal:  Interv Neuroradiol       Date:  2010-10-25       Impact factor: 1.610

3.  Pharmacological neutropenia prevents endothelial dysfunction but not smooth muscle functions impairment induced by middle cerebral artery occlusion.

Authors:  Olivier Pétrault; Thavarak Ouk; Sophie Gautier; Maud Laprais; Patrick Gelé; Michèle Bastide; Régis Bordet
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

4.  Neutrophils contribute to intracerebral haemorrhages after treatment with recombinant tissue plasminogen activator following cerebral ischaemia.

Authors:  Sophie Gautier; Thavarak Ouk; Olivier Petrault; Jacques Caron; Régis Bordet
Journal:  Br J Pharmacol       Date:  2009-02-04       Impact factor: 8.739

5.  Does plasmin have anticoagulant activity?

Authors:  Jane Hoover-Plow
Journal:  Vasc Health Risk Manag       Date:  2010-04-15

6.  Genome response to tissue plasminogen activator in experimental ischemic stroke.

Authors:  Glen C Jickling; Xinhua Zhan; Bradley P Ander; Renée J Turner; Boryana Stamova; Huichun Xu; Yingfang Tian; Dazhi Liu; Ryan R Davis; Paul A Lapchak; Frank R Sharp
Journal:  BMC Genomics       Date:  2010-04-21       Impact factor: 3.969

7.  Higher neutrophil counts before thrombolysis for cerebral ischemia predict worse outcomes.

Authors:  Ilaria Maestrini; Daniel Strbian; Sophie Gautier; Elena Haapaniemi; Solène Moulin; Tiina Sairanen; Nelly Dequatre-Ponchelle; Gerli Sibolt; Charlotte Cordonnier; Susanna Melkas; Didier Leys; Turgut Tatlisumak; Régis Bordet
Journal:  Neurology       Date:  2015-09-11       Impact factor: 9.910

Review 8.  Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis?

Authors:  Be'eri Niego; Robert L Medcalf
Journal:  J Cereb Blood Flow Metab       Date:  2014-06-04       Impact factor: 6.200

9.  Reperfusion-associated hemorrhagic transformation in SHR rats: evidence of symptomatic parenchymal hematoma.

Authors:  Erica C Henning; Lawrence L Latour; John M Hallenbeck; Steven Warach
Journal:  Stroke       Date:  2008-08-28       Impact factor: 7.914

10.  Safety evaluation of a recombinant plasmin derivative lacking kringles 2-5 and rt-PA in a rat model of transient ischemic stroke.

Authors:  Joseph C LaManna; Valery Novokhatny; Philip Scuderi; Stephen R Petteway; Vikram Arora; R Christian Crumrine; Victor J Marder; G McLeod Taylor; Constantinos P Tsipis
Journal:  Exp Transl Stroke Med       Date:  2012-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.